<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03597555</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL17_0375</org_study_id>
    <nct_id>NCT03597555</nct_id>
  </id_info>
  <brief_title>Sodium Oxybate in Idiopathic Hypersomnia</brief_title>
  <acronym>SODHI</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Tolerance of Sodium Oxybate in Patients Affected With Idiopathic Hypersomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      this study evaluates of the efficacy of sodium oxybate on excessive daytime sleepiness using
      Epworth sleepiness scale over 8 weeks compared to placebo
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bicentric, randomized, double-blind controlled study Outpatients aged from 18 to 60 years,
      suffering from current idiopathic hypersomnia (ICSD-3), recruited via medical consultations
      in the investigation centers Randomization in Xyrem or placebo arms after the inclusion
      visit,

      1.Screening Period (up to 15 days), 2.Titration Period (up to 45 days), 3.Maintenance Period
      (minimum 15 days), 4.Safety Follow-Up Period (14 days)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Epworth Sleepiness Scale (ESS) score at the end-point visit</measure>
    <time_frame>over 8 weeks</time_frame>
    <description>Evaluation of difference in sleepiness with ESS between the 2 groups. ESS scores range from 0 to 24; there is a risk of pathological daytime sleepiness if score is &gt; 10.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Idiopathic Hypersomnia</condition>
  <arm_group>
    <arm_group_label>Xyrem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xyrem (Sodium Oxybate), oral solution 500mg/mL First night after V1: Dose prescribed at 4.5 g per night (2.25 g x 2) for 2 weeks First night after V2: Dose increased to 6 g per night (3 g x 2) for 2 weeks, according to investigator's opinion, tolerance of drug and CGI-S First night after V3: Dose either maintained stable at 6 g or increased to 9 g per night (4.5 g x 2) with dose increments of 1.5 g per night (0.75 g x 2) every week, based on benefit-risk ratio, for 2 weeks.
First night after V4: Dose maintained at 9 g or reduced at 6 g per night according to benefit-risk ratio for 2 weeks. No dose adjustment during the Maintenance period.
First night after V5: Taper period. Dose decrease by 2.25 g x 2 every two days until complete withdrawal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebos</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Oxybate Oral Solution 500 MG/ML</intervention_name>
    <description>First night after V1: Dose prescribed at 4.5 g per night (2.25 g x 2) for 2 weeks First night after V2: Dose increased to 6 g per night (3 g x 2) for 2 weeks, according to investigator's opinion, tolerance of drug and CGI-S First night after V3: Dose either maintained stable at 6 g or increased to 9 g per night (4.5 g x 2) with dose increments of 1.5 g per night (0.75 g x 2) every week, based on benefit-risk ratio, for 2 weeks.
First night after V4: Dose maintained at 9 g or reduced at 6 g per night according to benefit-risk ratio for 2 weeks. No dose adjustment during the Maintenance period.
First night after V5: Taper period. Dose decrease by 2.25 g x 2 every two days until complete withdrawal</description>
    <arm_group_label>Xyrem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid</description>
    <arm_group_label>Placebos</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnostic of idiopathic hypersomnia (ICSD-3 criteria)

          -  Age between 18 and 60 years-old

          -  BMI between 18 and 35 kg/m2

          -  MSLT: mean sleep latency (MSL) ≤8 minutes and &lt; 2 SOREMPs, AND/OR total sleep time &gt;
             11h/24h on 24-hours long-term polysomnography

          -  Polysomnography recording: sleep efficiency &gt; 85%, total sleep time ≥6 hours, AHI
             &lt;10/hour, micro-arousals index &lt;15/hour, PLM index associated with micro-arousals
             &lt;10/hour.

          -  Absence of sleep deprivation, assessed by actigraphy or sleep logs

          -  ESS score ≥14 points

          -  Written informed consent

          -  National health insurance cover

        Exclusion Criteria:

          -  Current alcohol intake or treatment with modafinil, amphetamine, methylphenidate,
             mazindol, pitolisant, neuroleptics, sedative hypnotics, barbiturates, general
             anesthetics, myorelaxants, other CNS depressants, antidepressants*, anxiolytic drugs,
             anticonvulsive therapy, topiramate, inhibitors of GHB dehydrogenase (i.e. valproate,
             ethosuximide, phenytoin), budipine, dopamine antagonist antiemetics (except
             domperidone), opioids, benzodiazepines, Z-drugs, MAO inhibitors, COMT inhibitors, or
             sedative antihistamines. If patient has received such therapy, a washout-period of at
             least 15 days, or equivalent to 5 half-lives of the drug, prior to the inclusion in
             the study is required before starting treatment in this study.

             *30 days for antidepressants

          -  Previous intake of sodium oxybate

          -  Succinic semialdehyde dehydrogenase deficiency, porphyria

          -  Other central nervous system diseases: neurodegenerative diseases, seizure disorders
             or history of head trauma associated with loss of consciousness

          -  Lifetime history of suicide attempt or suicidal ideation in the past 6 months, prior
             history of psychotic episodes, current or recent history of a major depressive
             disorder (DSM-V), Beck depression inventory (BDI) &gt; 16 and/or item G&gt; 0

          -  History of chronic alcohol or drug abuse within the prior 12 months

          -  Malignant neoplastic disease requiring therapy within 12 months prior to Visit 1 or
             clinically relevant

          -  Heart failure, severe hypertension or other cardiovascular disease compromising the
             patient's wellbeing or ability to participate in this study

          -  Renal or hepatic impairment Compromised respiratory function

          -  Sleep-related breathing disorders (AHI ≥ 10/h)

          -  No regular sleep at night: shift work or other continuous non-disease-related life
             conditions

          -  Participation in another study of an investigational drug within the 28 days prior to
             Visit 1 or currently

          -  Hypersensitivity to any of the components of the study medication

          -  Pregnancy (βHCG positive) and breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves DAUVILLIERS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yves DAUVILLIERS, Pr</last_name>
    <phone>33 4 67 33 63 61</phone>
    <email>y-dauvilliers@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves Dauvilliers</last_name>
    </contact>
    <contact_backup>
      <last_name>Elisa Evangelista</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 13, 2018</study_first_submitted>
  <study_first_submitted_qc>July 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic Hypersomnia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disorders of Excessive Somnolence</mesh_term>
    <mesh_term>Hypersomnolence, Idiopathic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium Oxybate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

